Regimens | n (n = 612) | CINV [n (%)] |
---|
Grade 0-II (n = 339) | Grade III-IV (n = 273) |
---|
CAF | 59 | 36 (61.0) | 23 (39.0) |
CEF | 107 | 59 (55.1) | 48 (44.9) |
TEC | 57 | 29 (50.9) | 28 (49.1) |
TE | 122 | 74 (60.7) | 48 (39.3) |
TAC | 61 | 40 (65.6) | 21 (34.4) |
TA | 51 | 24 (47.1) | 27 (52.9) |
AC | 40 | 21 (52.5) | 19 (47.5) |
EC | 115 | 56 (48.7) | 59 (51.3) |
- Comparison between groups showed that the incidence of nausea and vomiting between the different chemotherapy groups was not statistically significant (chi-square test, P = 0.342)
-
CINV chemotherapy-induced nausea and vomiting, CAF cyclophosphamide, adriamycin, fluorouracil, CEF cyclophosphamide, epirubicin, and fluorouracil, AC adriamycin and cyclophosphamide, EC epirubicin and fluorouracil, TAC docetaxel, adriamycin, and cyclophosphamide, TEC docetaxel, epirubicin, and cyclophosphamide, TA pacilitaxel and adriamycin, TE docetaxel and epirubicin